白细胞介素-6靶向治疗前时代的中国Castleman病诊疗现状

Castleman Disease in China:State-of-the-art Technology Before the Era of IL-6 Targeted Therapy

Castleman病是纳入我国《第一批罕见病目录》的罕见血液系统疾病,该病临床异质性强,分为多种亚型。其中,特发性多中心型Castleman病(idiopathic multicentric Castleman disease, iMCD)病情重、预后差,是临床医师面临的重大挑战。白细胞介素(interleukin, IL)-6靶向药物(如司妥昔单抗)是国内外多个指南、共识推荐治疗iMCD的首选药物,2022年7月司妥昔单抗在国内上市,标志着我国针对iMCD的IL-6靶向治疗时代的开启。IL-6靶间治疗已在国内陆续展开,本文阐述过去20年间(IL-6靶向治疗前时代)中国Castleman病的诊疗现状,以及国内研究者在该领域取得的研究成果。

Castleman disease(CD)is a group of rare and heterogenous hematological diseases included in the‘Rare disease catalogue'of China.Among the different clinical subtypes of CD,idiopathic multicentric Castleman disease(iMCD)is characterized by symptomatic inflammatory symptoms with poor prognosis.Interleukin-6(IL-6)targeted therapy(eg.siltuximab)is now considered as the most important treatment option according to international and domestic treatment guidelines and consensus.On July 2022,siltuximab became available in Chinese market,heralding the era of IL-6 targeted therapy in China.Thus,it is a good time point to review the state-of-the-art technology in the field of diagnosis and treatment of CD.We also highlight some of the clinical investigations conducted by Chinese researchers.